胃腸病學市場規模、佔有率、成長分析，按類型、按分銷管道、按應用、按管理途徑、按地區 - 行業預測，2025-2032

2023年全球胃腸病學市場規模預計為374億美元，從2024年的626.5億美元成長到2032年的626.5億美元，預測期內（2025-2032年）複合年成長率為5.9%，預計將成長至2023年。

由於不良飲食習慣和老年人口增加導致胃腸道疾病盛行率不斷增加，胃腸道疾病市場正在經歷顯著成長。胃腸道疾病的快速增加導致住院和手術的增加，主要企業正在加緊生技藥品和生物相似藥的研發。此外，臨床試驗的擴大，截至 2021 年 5 月正在進行 6,443 項臨床試驗，展示了包括細胞療法和小分子在內的創新治療的強大管道。隨著醫療保健領域的發展，這些發展為有效治療方法提供了新的機會，並進一步支持未來幾年胃腸病學市場的成長。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

胃腸病學市場規模：按類型

• 市場概況
• 品牌
• 非專利的

胃腸病學市場規模：依分銷管道分類

• 市場概況
• 零售藥房
• 醫院藥房
• 網路藥房

胃腸病學市場規模：依應用分類

• 市場概況
• 克隆氏症
• 潰瘍性大腸炎
• GERD
• IBS
• 其他

胃腸病學市場規模：依給藥途徑分類

• 市場概況
• 可注射的
• 口頭及其他

消化系統疾病市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• AbbVie Inc.（US）
• Takeda Pharmaceutical Company Limited（Japan）
• AstraZeneca plc（UK）
• Bayer AG（Germany）
• Pfizer Inc.（US）
• Johnson & Johnson（US）
• Novartis AG（Switzerland）
• Merck & Co., Inc.（US）
• Sanofi SA（France）
• GlaxoSmithKline plc（UK）
• Boehringer Ingelheim International GmbH（Germany）
• Teva Pharmaceutical Industries Limited（Israel）
• Boston Scientific Corporation（US）
• Medtronic plc（Ireland）
• Olympus Corporation（Japan）
• Fujifilm Corporation（Japan）
• Stryker Corporation（US）
• Nestle Health Science（Switzerland）
• Danone SA（France）

結論和建議

Global Gastroenterology Market size was valued at USD 37.4 billion in 2023 and is poised to grow from USD 62.65 billion in 2024 to USD 62.65 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The gastroenterology market is witnessing significant growth, driven by the increasing prevalence of gastrointestinal diseases, largely attributable to poor dietary habits and a growing elderly population. The surge in gastrointestinal disorders has led to a rise in hospitalizations and surgical interventions, prompting biopharmaceutical companies to intensify their R&D efforts in biologics and biosimilars. Additionally, the expansion of clinical trials, with 6,443 ongoing studies as of May 2021, indicates a robust pipeline for innovative treatments, including cellular therapies and small compounds. As the healthcare landscape evolves, these developments present new opportunities for effective therapies, further propelling the growth of the gastroenterology market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroenterology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroenterology Market Segmental Analysis

Global Gastroenterology Market is segmented by type, distribution channel, application, route of administration and region. Based on type, the market is segmented into branded and generics. Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. Based on application, the market is segmented into crohn's disease, ulcerative colitis, Gerd, IBS and others. Based on route of administration, the market is segmented into injectable and oral & others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroenterology Market

The global gastroenterology market is being significantly influenced by the rising incidence of gastrointestinal diseases, such as gallstones, ulcerative colitis, hemorrhoids, and irritable bowel syndrome (IBS). Factors contributing to the increasing prevalence of both chronic and acute gastrointestinal conditions include unhealthy dietary choices, sedentary lifestyles, heightened stress levels, food sensitivities, and bacterial or viral infections. Consequently, there is a growing demand for various medications, including antacids, proton pump inhibitors, histamine H2-receptor antagonists, and antibiotics, to effectively manage these disorders and prevent related health complications. This surge in healthcare needs is propelling the expansion of the global market for gastroenterology therapeutics.

Restraints in the Global Gastroenterology Market

The global gastroenterology market is expected to encounter considerable challenges during the forecast period, primarily due to the escalating costs associated with treatments. Various gastrointestinal disorders, including chronic conditions like Crohn's disease and ulcerative colitis, require ongoing management to prevent recurrence and potential complications such as cancer. The comprehensive treatment expenses encompass medication costs, consultations, and hospital admissions, which significantly contribute to the overall financial burden. For instance, biologic therapies such as infliximab and vedolizumab can range from $6,000 to $8,700 per prescription, while monthly costs for some treatments can vary between $2,500 and $5,500. These increasing out-of-pocket expenses for treatments and procedures are likely to hinder the market's growth.

Market Trends of the Global Gastroenterology Market

The global gastroenterology market is poised for significant growth, fueled by the rising prevalence of gastrointestinal disorders like ulcerative colitis and Crohn's disease. Pharmaceutical and biotechnology companies are increasingly investing in research and development to innovate cutting-edge therapies, expanding their product pipelines to meet this growing demand. This trend is marked by a strong focus on developing revolutionary treatments that promise enhanced efficacy for patients. As both regional and global players ramp up their efforts in drug development, the global therapeutics market for gastrointestinal diseases is expected to thrive, presenting substantial opportunities for stakeholders over the forecast period.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Gastroenterology Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Gastroenterology Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Gastroenterology Market Size by Application & CAGR (2025-2032)

• Market Overview
• Crohn's Disease
• Ulcerative Colitis
• Gerd
• IBS
• Others

Global Gastroenterology Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Injectable
• Oral & Others

Global Gastroenterology Market Size & CAGR (2025-2032)

• North America (Type, Distribution Channel, Application, Route Of Administration)
  • US
  • Canada
• Europe (Type, Distribution Channel, Application, Route Of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Distribution Channel, Application, Route Of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Distribution Channel, Application, Route Of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Distribution Channel, Application, Route Of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Limited (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Health Science (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danone S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations